Tislelizumab
BGB-A317-311
Phase 3 small_molecule completed
Quick answer
Tislelizumab for Esophageal Squamous Cell Carcinoma (ESCC) is a Phase 3 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed